FOXO4 (10mg)

$320.00

SKU: YPB.255 Category:

Description

A single-component research material supplied for controlled research environments. FOXO4 (10 mg) is a synthetic peptide fragment used in research exploring cellular senescence, apoptosis regulation, and FOXO transcription factor signaling pathways in controlled model systems.


Composition

• FOXO4
Appearance: Lyophilized powder in a sealed research vial


Research Focus (non-clinical)

• Investigation of FOXO4-p53 interaction in cellular senescence models
• Studies of apoptosis induction pathways in aging research
• Peptide identity and purity verification via HPLC/LC-MS
• Stability and solubility profiling under various laboratory storage conditions

For qualified research professionals and institutional laboratories. Not for human use.


Documentation & Quality Assurance

Each lot is sourced through our verified global supply chain with emphasis on traceability and quality control. We work diligently to obtain and maintain third-party analytical reports (HPLC/LC-MS) and Certificates of Analysis for each batch, as part of our ongoing quality process. These documents are reviewed internally and displayed as they become available. Independent third-party testing is also performed on select lots to confirm identity, purity, and alignment with our internal specifications.


Important Notice

This product is intended for laboratory research use only. It is not intended for human or veterinary use, and must not be used for diagnostic, therapeutic, or clinical purposes.
This material is not a drug, medical device, or dietary supplement, and has not been evaluated by the U.S. Food and Drug Administration.


Quality & Manufacturing

All materials are sourced from carefully vetted domestic and international manufacturing partners who follow quality systems consistent with ISO and cGMP principles. Each supplier is reviewed for reliability, documentation integrity, and transparency in testing.

We require a verified purity of 99% or higher and perform independent third-party spot testing to confirm that select lots meet our internal standards for identity, purity, and composition. Where available, endotoxin testing results are included on Certificates of Analysis to verify laboratory purity; their inclusion is for research quality assessment only and does not imply suitability for human or veterinary use.

All research materials are sealed for integrity and packaged for stability during storage and transport from manufacturing through final delivery.

Additional information

Weight 0.2 lbs

Storage Instructions

All our research peptides are manufactured using a lyophilization (freeze-drying) process. This method is designed to maintain product integrity and allows vials to remain stable during shipping for approximately 3–4 months.

Once a vial is reconstituted with bacteriostatic water, it should be stored in the refrigerator to help maintain stability. Under these conditions, reconstituted material is generally considered stable for up to 30 days.

Lyophilization is a dehydration technique in which compounds are frozen and then exposed to low pressure. This causes the water in the vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure. This powder can be kept at room temperature until reconstitution.

Upon receipt, products should be stored away from heat and light. For short-term use, refrigeration at approximately 4°C (39°F) is suitable. For long-term storage (several months to years), vials may be placed in a freezer at approximately -80°C (-112°F). Freezing is the preferred method for preserving product stability over extended periods.

⚠️ Important Notice: These products are intended for research use only. Not for human consumption.

Certificate of Analysis

Every batch undergoes rigorous third-party laboratory testing to verify identity, purity (≥98%), and quality before release.

View Certificate of Analysis
Third-Party Verified ≥98% Purity HPLC & MS Tested

Research Use Only

These studies reference research-grade peptides for laboratory and scientific investigation only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.

Published Scientific Research

Peer-reviewed laboratory research investigating research peptides from leading scientific databases

Mechanism Study
PubMed

FOXO transcription factors in Alzheimer's Disease: balancing neuroprotection and neuronal degeneration.

Molecular biology reports 2026

FOXOs regulate antioxidant defenses, autophagy, mitochondrial quality control, and apoptosis by functioning downstream of insulin/PI3K-Akt and stress-responsive pathways. This context-dependent activity enables FOXOs to act as dual regulators: brief activation improves proteostasis, oxidative stress tolerance, and synaptic resilience, whereas dysregulated signaling triggers pro-apoptotic and neurodegenerative pathways.

View Full Study
Molecular Analysis
PubMed

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.

Frontiers in bioengineering and biotechnology 2025

This study innovatively focuses on the mechanism by which FOXO4-DRI induces apoptosis in senescent endothelial cells, demonstrating that it functions by activating the p53/BCL-2/Caspase-3 signaling pathway to promote selective apoptosis of these cells. Additionally, it investigates changes in endothelial cell function in senescent endothelial cells induced by oxygen-glucose deprivation (OGD), as well as the protein expression and interaction in the FOXO4-P53 signaling pathway.

View Full Study
In Vitro Study
PubMed

FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.

Naunyn-Schmiedeberg's archives of pharmacology 2023

FOXO4-D-Retro-Inverso (FOXO4-DRI), a synthesis peptide as a specific FOXO4 blocker, selectively induced dissociation of the FOXO4-p53 complex and nuclear exclusion of p53. Simultaneously, the p53 signaling pathway has been reported to activate in fibroblasts isolated from IPF fibrotic lung tissues and the p53 mutants cooperate with other factors that have the ability to disturb the synthesis of ECM.

View Full Study
Molecular Analysis
PubMed

Bioinformatics procedure for investigating senolytic (anti-aging) agents: A digital signal processing technique.

Aging medicine (Milton (N.S.W)) 2023

We found that enhanced senescence 2 (ES2) has a higher affinity for CR3 and BDB than FOXO4 and DRI, and that the interaction between CR3 and BDB is crucial for aging. Our findings are consistent with previous studies and reveal new insights into the mechanisms of senescence and senolytics.

View Full Study
In Vitro Study
PubMed

FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.

Journal of cellular and molecular medicine 2022

In this study, we explored the effect of FOXO4-DRI on bleomycin (BLM)-induced PF mouse model. We found that similar as the approved medication Pirfenidone, FOXO4-DRI decreased senescent cells, downregulated the expression of senescence-associated secretory phenotype (SASP) and attenuated BLM-induced morphological changes and collagen deposition.

View Full Study
Laboratory Research
PubMed

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From Expanded Human Chondrocytes.

Frontiers in bioengineering and biotechnology 2021

However, the cartilage tissue generated from FOXO4-DRI pretreated PDL9 cells displayed lower expression of senescence-relevant secretory factors than that from the untreated control group.

View Full Study